Prostate cancer is the most commonly diagnosed cancer in men in the United States and the second leading cause of cancer death among men worldwide. It is also one of the most biologically complex cancers to study in a laboratory setting, largely because of the central role that androgen hormones play in driving tumor growth and because of how dramatically the disease changes as it progresses from hormone-sensitive to castration-resistant disease.
Three cell lines sit at the center of most prostate cancer research: LNCaP, PC-3, and DU145. Each one was derived from a different stage and site of prostate cancer metastasis, each carries a different mutation profile, and each models a different phase of disease biology. Together, they form a complementary panel that covers the spectrum from androgen-sensitive to androgen-independent prostate cancer.
This guide explains what each line is, how they compare to one another, when to use each one, and which additional lines researchers reach for when the classic trio is not enough.
Understanding Androgen Sensitivity in Prostate Cancer Research
Before comparing individual cell lines, it helps to understand why androgen sensitivity is such a central concept in prostate cancer biology. The androgen receptor, or AR, is a transcription factor that, when activated by testosterone or dihydrotestosterone, drives the expression of genes that promote cell survival and proliferation. In early-stage prostate cancer, this AR signaling is the primary growth driver.
Androgen deprivation therapy, which lowers testosterone levels or blocks androgen receptor activity, is the cornerstone of treatment for advanced prostate cancer. Most tumors respond initially, but the majority eventually develop resistance and progress to castration-resistant prostate cancer (CRPC), a state where tumor growth continues despite low androgen levels.
The three classic prostate cancer cell lines model different points along this progression. LNCaP represents androgen-sensitive disease. PC-3 and DU145 represent androgen-independent, castration-resistant disease. This distinction shapes almost every decision about which line to use for a given experiment.
LNCaP: The Androgen-Sensitive Standard
Origin and Background
LNCaP stands for Lymph Node Carcinoma of the Prostate. The cell line was established in 1977 from a metastatic lesion taken from the left supraclavicular lymph node of a 50 year old male patient with treatment-refractory prostate cancer. Despite originating from a metastatic site, LNCaP cells retain androgen sensitivity, which makes them the standard model for studying hormone-responsive prostate cancer.
Key Genetic Features
LNCaP cells carry several clinically relevant mutations. The most important is a point mutation in the androgen receptor gene that renders the AR hypersensitive to androgens and also allows it to be activated by non-androgen ligands including estrogens, progesterone, and even some anti-androgens. This promiscuous AR activation is actually characteristic of what happens clinically when some patients treated with anti-androgen drugs develop paradoxical tumor growth.
LNCaP cells lack functional PTEN, a tumor suppressor gene that normally inhibits the PI3K/AKT signaling pathway. PTEN loss is one of the most common genetic events in prostate cancer and leads to constitutive activation of AKT, promoting cell survival and resistance to apoptosis. This makes LNCaP a relevant model for studying PI3K pathway inhibitors in a prostate cancer context.
LNCaP cells express prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and other markers of prostatic epithelial differentiation, which makes them useful for studies evaluating PSA-based drug responses and PSMA-targeted therapies.
Biological Characteristics
LNCaP cells grow as loosely adherent clusters and have a doubling time of approximately 60 to 90 hours, making them slower-growing than PC-3 or DU145. They are sensitive to androgens and respond to stimulation with dihydrotestosterone by increasing proliferation and PSA secretion. Conversely, androgen deprivation suppresses their growth, which is the in vitro equivalent of the clinical response seen with androgen deprivation therapy.
One practical challenge with LNCaP is that long-term culture can lead to phenotypic drift, with cells gradually losing androgen sensitivity over many passages. Researchers should use low-passage cells and authenticate regularly to ensure the cells being studied still reflect the intended biology.
Best Uses for LNCaP
LNCaP is the first choice for studies of androgen receptor biology, hormone-responsive prostate cancer, anti-androgen drug evaluation, PSA regulation, and PSMA-targeted therapy development. It is also used in studies of the PI3K/AKT pathway and in research examining the transition from androgen-sensitive to castration-resistant disease.
PC-3: Modeling Aggressive, Androgen-Independent Disease
Origin and Background
PC-3 was established in 1979 from a bone metastasis of a 62 year old male patient with grade IV prostate cancer who had not responded to estrogen therapy or radiation. The bone metastasis origin is clinically significant: prostate cancer frequently spreads to bone in its advanced stages, and bone metastases are particularly difficult to treat and responsible for much of the morbidity associated with advanced prostate cancer.
Key Genetic Features
PC-3 cells do not express the androgen receptor and do not produce PSA. They are completely androgen-independent, meaning their growth is not influenced by androgen levels or anti-androgen treatments. PC-3 cells carry mutant TP53 and also lack PTEN, driving constitutive PI3K/AKT signaling. They are highly aneuploid, with a complex karyotype reflecting the genetic instability characteristic of late-stage metastatic cancer.
PC-3 cells show high levels of expression of genes associated with invasion and metastasis, including matrix metalloproteinases and integrins involved in adhesion to bone matrix. This expression profile reflects their origin from a bone metastatic lesion and makes them relevant for studying the mechanisms of prostate cancer bone tropism.
Biological Characteristics
PC-3 cells grow rapidly, with a doubling time of approximately 22 to 33 hours, significantly faster than LNCaP. They grow as adherent monolayers and are highly invasive in in vitro assays. PC-3 cells form tumors reliably in immunodeficient mouse models when injected subcutaneously or intraosseously, and intraosseous injection produces osteolytic bone lesions that model what is seen clinically in patients with prostate cancer bone metastases.
Best Uses for PC-3
PC-3 is the standard choice for studying castration-resistant prostate cancer, bone metastasis biology, invasion and migration assays, and drug resistance mechanisms in androgen-independent disease. It is frequently used in combination with LNCaP to compare drug effects across androgen-sensitive and androgen-independent contexts.
DU145: The Brain Metastasis-Derived Model
Origin and Background
DU145 was established in 1978 from a metastatic lesion in the brain of a prostate cancer patient. Brain metastases from prostate cancer are uncommon compared to bone metastases but represent a particularly aggressive disease manifestation. Like PC-3, DU145 was derived from a metastatic site and models late-stage, treatment-refractory prostate cancer.
Key Genetic Features
DU145 cells do not express the androgen receptor and do not produce PSA, placing them in the androgen-independent category alongside PC-3. DU145 carries mutant TP53 but, unlike PC-3, retains wild-type PTEN. This difference in PTEN status is one of the key genetic distinctions between DU145 and PC-3 and has practical implications for studies of PI3K pathway inhibitors: PC-3 cells with PTEN loss would be expected to respond differently to PI3K inhibitors than DU145 cells with intact PTEN.
DU145 cells express epidermal growth factor receptor (EGFR) at relatively high levels, making them a model for studying EGFR-targeted therapies in a prostate cancer context. They also show moderate expression of several epithelial markers, suggesting a phenotype intermediate between epithelial and mesenchymal.
Biological Characteristics
DU145 cells grow as adherent monolayers with a doubling time of approximately 34 hours, placing them between LNCaP and PC-3 in terms of growth rate. They are tumorigenic in immunodeficient mice and moderately invasive in in vitro assays, though generally less aggressive than PC-3 in invasion and migration experiments.
Best Uses for DU145
DU145 is used for studies of androgen-independent prostate cancer, EGFR-targeted therapy evaluation, and comparative studies with PC-3 where PTEN status needs to be a controlled variable. It is frequently included in three-line panels alongside LNCaP and PC-3 to provide broader coverage of prostate cancer biology.
Side-by-Side Comparison: LNCaP vs PC-3 vs DU145
The table below summarizes the key differences between the three classic prostate cancer cell lines:
Androgen Receptor Expression: LNCaP is AR-positive with a gain-of-function mutation. PC-3 is AR-negative. DU145 is AR-negative.
PSA Expression: LNCaP expresses PSA. PC-3 does not. DU145 does not.
TP53 Status: LNCaP carries wild-type TP53. PC-3 carries mutant TP53. DU145 carries mutant TP53.
PTEN Status: LNCaP lacks PTEN. PC-3 lacks PTEN. DU145 retains wild-type PTEN.
Metastasis Site of Origin: LNCaP from lymph node. PC-3 from bone. DU145 from brain.
Doubling Time: LNCaP approximately 60 to 90 hours. PC-3 approximately 22 to 33 hours. DU145 approximately 34 hours.
Androgen Sensitivity: LNCaP is androgen-sensitive. PC-3 is androgen-independent. DU145 is androgen-independent.
Additional Prostate Cancer Cell Lines Worth Knowing
22Rv1
22Rv1 has become one of the most important prostate cancer cell lines of the past decade. It was derived from a xenograft that was serially propagated in mice after castration, making it a model of castration-resistant prostate cancer that emerged through androgen deprivation therapy. 22Rv1 cells express both full-length androgen receptor and AR splice variant 7 (AR-V7), a constitutively active truncated form of AR that lacks the ligand-binding domain and is therefore resistant to enzalutamide and abiraterone, the two main second-generation anti-androgen drugs used clinically. AR-V7 expression in patients is a biomarker of resistance to these drugs, making 22Rv1 one of the most clinically relevant models for studying treatment-resistant CRPC.
VCaP
VCaP was derived from a vertebral bone metastasis of a patient with hormone-refractory prostate cancer. It is one of the few prostate cancer cell lines to carry the TMPRSS2-ERG gene fusion, which is the most common chromosomal rearrangement in prostate cancer, occurring in approximately 50 percent of tumors. VCaP cells are highly amplified for the androgen receptor gene and express very high levels of AR protein, making them a model for AR amplification-driven castration resistance. VCaP cells are slow-growing and technically challenging to work with, but their unique genetic features make them valuable for specific research applications.
C4-2 and C4-2B
C4-2 is a castration-resistant derivative of LNCaP generated by co-inoculating LNCaP cells with stromal cells in castrated mice. It retains AR expression but has acquired the ability to grow without androgen stimulation, modeling the clinical transition from hormone-sensitive to castration-resistant disease. C4-2B is a bone-metastatic subline derived from C4-2 that preferentially homes to bone when injected intravenously in mice, making it valuable for bone metastasis research. Together, LNCaP, C4-2, and C4-2B form a stepwise progression model from androgen-sensitive primary disease to androgen-independent bone metastasis.
How to Choose the Right Prostate Cancer Cell Line
Androgen Sensitivity Studies
Use LNCaP for androgen-sensitive disease. For studying the transition to castration resistance, the LNCaP to C4-2 progression model provides the most controlled experimental design. For AR splice variant and enzalutamide resistance research, 22Rv1 is the standard choice.
Bone Metastasis Research
PC-3 is the most commonly used line for bone metastasis studies. C4-2B provides a model that retains AR expression while also showing bone-homing behavior. Both are used in intraosseous and intracardiac injection models. These applications connect directly with broader cancer research questions around metastatic prostate cancer mechanisms and treatment strategies.
Drug Screening Panels
For broad drug screening across prostate cancer biology, a three-line panel of LNCaP, PC-3, and DU145 covers androgen-sensitive disease, androgen-independent PTEN-null disease, and androgen-independent PTEN-wild-type disease. Adding 22Rv1 extends coverage to AR-V7 mediated resistance. This panel approach is standard in drug discovery and screening workflows where demonstrating activity across multiple prostate cancer subtypes is required before advancing a compound.
TMPRSS2-ERG Fusion Research
VCaP is the only commonly available prostate cancer cell line that naturally carries the TMPRSS2-ERG fusion. Researchers studying this rearrangement, which affects approximately half of all prostate cancers, must use VCaP or engineered models where the fusion has been introduced into another cell line.
Authentication and Quality Control
Prostate cancer cell lines, particularly LNCaP and PC-3, have documented histories of cross-contamination and phenotypic drift in the literature. Given how central androgen receptor status is to prostate cancer research, using a cell line that has lost AR expression through contamination or extended passaging would fundamentally compromise experimental results. STR profiling authentication before use is essential. You can read more about why this matters and how the process works in our guide on cell line authentication and STR profiling.
Frequently Asked Questions
What is the difference between LNCaP and PC-3?
LNCaP is androgen-sensitive, expresses the androgen receptor and PSA, and models hormone-responsive prostate cancer. PC-3 is androgen-independent, does not express AR or PSA, and was derived from a bone metastasis, making it a model of aggressive, castration-resistant disease.
Are PC-3 and DU145 the same?
No. Both are androgen-independent and AR-negative, but they differ in PTEN status (PC-3 lacks PTEN, DU145 retains it), TP53 mutation profile, metastatic site of origin (bone vs brain), growth rate, and invasive behavior. These differences make them complementary rather than interchangeable models.
What is 22Rv1 used for?
22Rv1 is used primarily for studying castration-resistant prostate cancer driven by AR splice variant 7 (AR-V7). It is the standard model for evaluating resistance to enzalutamide and abiraterone, and for studying strategies to overcome AR-V7 mediated drug resistance.
Which prostate cancer cell line expresses PSA?
LNCaP is the primary prostate cancer cell line that expresses PSA. VCaP also expresses PSA but is technically more challenging to work with. PC-3 and DU145 do not express PSA.
What does androgen-independent mean in prostate cancer cell lines?
Androgen-independent means the cells can proliferate without androgen stimulation and do not respond to androgen deprivation therapy. PC-3 and DU145 are androgen-independent, reflecting the biology of castration-resistant prostate cancer seen clinically in patients who have progressed through hormone therapy.
Which prostate cancer cell line is best for bone metastasis research?
PC-3 is the most commonly used for bone metastasis studies because of its aggressive phenotype and its origin from a bone metastatic lesion. C4-2B is preferred when AR expression needs to be retained, as it combines castration resistance with a preference for bone colonization in mouse models.
Do prostate cancer cell lines need to be authenticated?
Yes. LNCaP and PC-3 in particular have documented contamination and drift issues. Since androgen receptor status is critical to interpreting prostate cancer experiments, using cells that have lost AR expression through contamination would invalidate results. STR profiling before use is strongly recommended.